Company Focus
Amgen
Latest Amgen News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Related News
Insights
Company Spotlight
A biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
Latest News & Features of interest to Amgen
Biotechnology
Agenus has revealed via a Securities and Exchange Commission (SEC) filing that US pharma major Bristol Myers Squibb (NYSE: BMS) was pulling out of a licensing deal. 5 August 2024
Biotechnology
German biotech BioNTech today reported financial results for the three ended June 30, 2024, which failed to impress.. 5 August 2024
Biotechnology
Shares of Genmab dipped 2.6% to 1,867 kroner in early trading, as the Danish drugmaker revealed that the return of rights to acasunlimab by German biotech BioNTech 5 August 2024
Pharmaceutical
US rare disease drug focussed company Zevra Therapeutics saw its shares rise nearly 43% to $9.00 in after-hours trading on Friday as it announced a positive development for its arimoclomol. 5 August 2024
Biotechnology
Clinical trial results featured heavily in the news last week, first with Dutch biotech NewAmsterdam releasing data on its hypercholesterolemia candidate obicetrapib. US drug developer MacroGenics announced receipt of a $100 million milestone from Incyte relating to progress in its deal on Zynyz and updated on the development of prostate cancer drug vobra duo. Germany’s BioNTech announced top-line Phase II results of its mRNA cancer immunotherapy BNT111. Also, US pharma major Eli Lilly released new data on its GLP-1 drug tirzepatide – already marketed for diabetes and obesity under the trade names Mounjaro and Zepbound, respectively - in heart failure. 4 August 2024
Pharmaceutical
Pharma giants are vehemently opposing the Indian government's proposal to apply the trade margin rationalization (TMR) formula to certain drugs with the aim of reducing drug prices. 2 August 2024
Biotechnology
FibroGen (Nasdaq: FGEN) has announced it will lay off around 75% of its US staff following disappointing results from late-stage trials of pamrevlumab. 2 August 2024
Biotechnology
Dallas, Texas-based Instil Bio and China’s ImmuneOnco Biopharmaceuticals have announced a license and collaboration agreement. 2 August 2024
Pharmaceutical
Chugai Pharmaceutical says its Taiwan subsidiary (CPT) has obtained an import drug license from the Taiwan Food and Drug Administration (TFDA) for Alecensa (alectinib) 2 August 2024
Pharmaceutical
BridGene Biosciences is expanding its collaboration with Belgian firm Galapagos (Euronext: GLPG) to advance drug discovery for challenging cancer targets. 2 August 2024
Latest In Brief for Amgen
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Latest Relevant Ones To Watch News
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
14 November 2024
13 November 2024
29 October 2024
28 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze